Pre-made Relatlimab benchmark antibody ( Whole mAb, anti-LAG3 therapeutic antibody, Anti-CD223 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-476
Pre-Made Relatlimab biosimilar, Whole mAb, Anti-LAG3 Antibody: Anti-CD223 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Relatlimab (INN; development code BMS-986016) is a monoclonal antibody designed for the treatment of melanoma.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Relatlimab biosimilar, Whole mAb, Anti-LAG3 Antibody: Anti-CD223 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II/III|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Bristol-Myers Squibb;Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|
|Conditions Active||Malignant melanoma;Colorectal cancer;Gastric cancer;Renal cell carcinoma;Solid tumours;Oesophageal cancer;Glioblastoma|
|Conditions Discontinued||Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Hodgkin's disease;Mantle-cell lymphoma;Non-Hodgkin's lymphoma|